Anadis & SPC Ardmona Solidify Healthy Functional Food Collaboration.Companies to develop a pipeline of innovative functional food for healthy lifestyle, to be launched in coming years MELBOURNE, Australia -- Anadis Limited (ASX ASX See: Australian Stock Exchange : ANX ; OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). : ANDIY), a research driven biopharmaceutical company had announced significant progress in its collaboration with SPC Ardmona Operations Limited (SPCA SPCA serum prothrombin conversion accelerator (coagulation factor VII). SPCA abbr. serum prothrombin conversion accelerator SPCA, n an acronym for serum p ), a fully-owned subsidiary of Coca-Cola Amatil Ltd (ASX: CCL) in the development of lifestyle, health and wellness foods. The companies are developing technologies that will result in a pipeline of innovative and healthy functional food products for launch in coming years. These developments will enjoin technologies developed by Anadis, with the innovative efforts of SPC Ardmona, a company renowned for taking packaged fruit into new technologies. "We find the Anadis R&D team to be creative in their ability to rapidly develop prototypes for products that are both tasty and healthy. Healthy food has always been an important part of our growth strategy and Anadis now plays an important role in a major project in our Technology and Innovation platform. We are exploring, in conjunction with Anadis, a variety of products to deliver the healthiness of fruits in unique and tasty ways" says Nigel Garrard, Managing Director of SPC Ardmona. SPC recently restructured its R&D function to create the new Technology and Innovation Group, based in Shepparton, Victoria, Australia. "We now have a greater capacity for fundamental research, innovation, functional foods, and demanding technologies" says SPC Ardmona in its announcement. Dr. Grant Rawlin, VP R&D of Anadis said: "SPC has incredible experience in bringing consumer products into the market, and we are proud that our past investments in R&D for polyclonal antibodies and BioShielding oral antibody delivery technologies could impact an even broader market through daily consumption of healthy foods as part of a healthy lifestyle." The global functional foods market is a dynamic and rapidly growing segment of the food industry. Research expects it to constitute 5% of the world food market by the year 2010, or around US$165Billion (Market Research, 2004). Functional food is rapidly emerging from being a niche market to a mainstream market category, with large food companies such as Coca Cola (NYSE NYSE See: New York Stock Exchange : KO), Nestle (NESN NESN New England Sports Network .VX), Kraft (NYSE:KFT), and Groupe Danone (BN.PA) becoming key players in the global functional foods and beverages marketplace. Solid science regarding safety and efficacy is pivotal in ensuring future market success and consumer confidence. Dr Oren Fuerst, VP Business Development of Anadis, said: "Collaborations in the functional food arena are becoming an important part of our activities, which cover numerous aspects of the health care sector. Partners from the food and beverage F&B is a common abbreviation in the United States and Commonwealth countries, including Hong Kong. F&B is typically the widely accepted abbreviation for "Food and Beverage," which is the sector/industry that specializes in the conceptualization, the making of, and delivery of foods. industry are starting to realize the value of our strong scientific foundation in the bioactive ingredients arena and how this could be adapted in the creation of new products that are both healthy as well as tasty. The collaboration with Coca Cola's SPC Ardmona demonstrates another significant growth path of our business." About Anadis Limited Anadis Limited (ASX: ANX) is a research driven biopharmaceutical company focused on antibody and other dairy derived bioactive ingredients as health products. Its all-natural, orally administered dairy-derived platform, and its regulatory classification as GRAS GRAS - A public domain graph-oriented database system for software engineering applications from RWTH Aachen. (Generally Regarded as Safe) allows for a significantly shorter time frame from bench to market compared with typical biotechnology products. The platform also possesses dramatically lower manufacturing costs and higher scalability compared to typical antibody-based health solutions. The company is addressing a variety of unmet health needs with broad market demand, including: Oral and GI Mucositis; Inflammatory Bowel disease inflammatory bowel disease n. Abbr. IBD Any of several incurable and debilitating diseases of the gastrointestinal tract characterized by inflammation and obstruction of parts of the intestine. (IBD IBD abbr. inflammatory bowel disease Inflammatory bowel disease (IBD) Disease in which the lining of the intestine becomes inflamed. Mentioned in: Amebiasis IBD 1. ); Irritable Bowel Syndrome irritable bowel syndrome (IBS), condition characterized by frequently alternating constipation and diarrhea in the absence of any disease process. It is usually accompanied by abdominal pain, especially in the lower left quadrant, bloating, and flatulence. (IBS IBS Irritable bowel syndrome, see there ); Travellers' Diarrhea; and Influenza. |
|
||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion